Iloperidone redux: A dissection of the drug approval package for this newly commercialised second-generation antipsychotic

International Journal of Clinical Practice

Volumn 64, Issue 6, 2010, Pages 707-718

  Citrome, L ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANAPT; HALOPERIDOL; ILOPERIDONE; OLANZAPINE; PLACEBO; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AKATHISIA; BODY TEMPERATURE; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DATA SYNTHESIS; DEMENTIA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG INFORMATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG PACKAGING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEART RATE; HEMATOCRIT; HUMAN; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PEER REVIEW ORGANIZATION; PRIORITY JOURNAL; PULSE RATE; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; ISOXAZOLES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77950656299     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02344.x     Document Type: Review

References (12)

1. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009 63 : 1237 1248.
2. Vanda Pharmaceuticals. Vanda Pharmaceuticals Announces Receipt of not Approvable Letter From FDA for Iloperidone. Press release, 28 July 2008. http://phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol- newsArticle&ID=1179851&highlight (accessed December 2009).
3. Novartis. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia. Press release, 12 October 2009. http://www.novartis.com/newsroom/media-releases/en/ 2009/1346595.shtml (accessed December 2009).
4. FDA. Drug Approval Package. Fanapt (Iloperidone) Tablets. 12 June 2009. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022192s000TOC.cfm (accessed December 2009).
5. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009 10 : 1917 1928.
6. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009 63 : 1762 1784.
7. Food and Drug Administration. [Docket No. 95-0230] Statement regarding the demonstrations of effectiveness of human drug products and devices. Fed Regist 1995 60 : 39180 39181.
8. Vanda Pharmaceuticals. Fanapt (Iloperidone) Tablets. http://www.fanaptus. com/assets/Newark%20Trade%20PI%2072483-10%20Fanapt%20full%20Master.pdf (accessed January 2010).
9. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009 39 : 1591 1602.
10. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 373 : 31 41.
11. Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009 166 : 152 163.
12. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials Mol Psychiatry 2009 14 : 429 447.